compound introduction
XY101 is a potent, selective, metabolically stable and orally available RORγ inverse agonist with an IC 50 of 30 nM and a K d of 380 nM In Vitro XY101 potently inhibits cell growth, colony formation, and the expression of androgen receptor (AR), AR-V7 and prostate-specific antigen (PSA). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo XY101 exhibits significant antitumor activities during the treatment period with tumor growth inhibition and is well tolerated without obvious body weight loss . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 30 nM (RORγ), Kd: 380 nM (RORγ)
